外科理论与实践

外科理论与实践 >

2023 , Vol. 28 >Issue 02: 177 - 180

DOI: https://doi.org/10.16139/j.1007-9610.2023.02.17

综述

外泌体在胃癌中的研究展望

展开
  • 上海交通大学医学院附属新华医院普通外科，上海 200092

收稿日期: 2021-12-30

  网络出版日期: 2023-06-06

收起

Exosome in gastric cancer: research and perspective

Expand
  • Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2021-12-30

  Online published: 2023-06-06

Fold

摘要

外泌体是直径40~150 nm的细胞外囊泡，广泛分布于各种体液中。我国胃癌占消化道恶性肿瘤的首位。外泌体内含物以多种途径参与胃癌的发生、发展、转移及肿瘤的微环境。外泌体可在胃癌早期诊断和治疗中发挥作用，作为早期的无创生物学标志物，也展现出药物运载体的潜能。本文综述近年来外泌体在胃癌发病机制和治疗中的深入研究。

关键词： 胃癌; 外泌体; miRNA

本文引用格式

范清泉, 宋晓玲, 顾钧 . 外泌体在胃癌中的研究展望[J]. 外科理论与实践, 2023 , 28(02) : 177 -180 . DOI: 10.16139/j.1007-9610.2023.02.17

Abstract

Exosomes are extracellular vesicles of 40-150 nm in size, which are widely distributed in various body fluids. Gastric cancer is the most common digestive tract malignancy in China. Exosomes are involved in the malignant evolution of gastric cancer in multiple ways including growth, progression, metastasis and microenvironment of tumor. Exosomes might be a non-invasive biological marker for early diagnosis of gastric cancer and have also shown potential as drug carriers in the treatment of gastric cancer. This article reviews recent research on exosomes in the pathogenesis and treatment of gastric cancer.

Key words： Gastric cancer; Exosome; miRNA

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251):635-648.
[4] PAN B T, JOHNSTONE R M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor[J]. Cell, 1983, 33(3):967-978.
[5] DOYLE L M, WANG M Z. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis[J]. Cells, 2019, 8(7):727.
[6] VANNIEL G, D'ANGELO G, RAPOSO G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol, 2018, 19(4):213-228.
[7] RAPOSO G, STOORVOGEL W. Extracellular vesicles: exosomes, microvesicles, and friends[J]. J Cell Biol, 2013, 200(4):373-383.
[8] ZHANG L, YU D. Exosomes in cancer development, metastasis, and immunity[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(2):455-468.
[9] HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5):646-674.
[10] SHI S S, ZHANG H P, YANG C Q, et al. Exosomal miR-155-5p promotes proliferation and migration of gastric cancer cells by inhibiting TP53INP1 expression[J]. Pathol Res Pract, 2020, 216(6):152986.
[11] YOON J H, ASHKTORAB H, SMOOT D T, et al. Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells[J]. Gastric Cancer, 2020, 23(5):848-862.
[12] NAKAMURA M, ONO Y J, KANEMURA M, et al. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum[J]. Gynecol Oncol, 2015, 139(2):345-354.
[13] ZHU M, ZHANG N, HE S, et al. Exosomal miR-106a derived from gastric cancer promotes peritoneal metastasis via direct regulation of Smad7[J]. Cell Cycle, 2020, 19(10):1200-1221.
[14] LI Q, LI B, LI Q, et al. Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition[J]. Cell Death Dis, 2018, 9(9):854.
[15] WANG J, GUAN X, ZHANG Y, et al. Exosomal miR-27a derived from gastric cancer cells regulates the transformation of fibroblasts into cancer-associated fibroblasts[J]. Cell Physiol Biochem, 2018, 49(3):869-883.
[16] ZHANG X, SHI H, YUAN X, et al. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration[J]. Mol Cancer, 2018, 17(1):146.
[17] WANG F, LI B, WEI Y, et al. Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression[J]. Oncogenesis, 2018, 7(5):41.
[18] XIA X, WANG S, NI B, et al. Hypoxic gastric cancer-derived exosomes promote progression and metastasis via miR-301a-3p/PHD3/HIF-1α positive feedback loop[J]. Oncogene, 2020, 39(39):6231-6244.
[19] LI W, LI C, ZHOU T, et al. Role of exosomal proteins in cancer diagnosis[J]. Mol Cancer, 2017, 16(1):145.
[20] XIA Y, HU X, DI K, et al. Combined detection of exosome concentration and tumor markers in gastric cancer[J]. J Biomed Nanotechnol, 2020, 16(2):252-258.
[21] TANG S, CHENG J, YAO Y, et al. Combination of four serum exosomal miRNAs as novel diagnostic biomarkers for early-stage gastric cancer[J]. Front Genet, 2020, 11(4):237.
[22] FU H, YANG H, ZHANG X, et al. Exosomal TRIM3 is a novel marker and therapy target for gastric cancer[J]. CA Cancer J Clin, 2018, 37(1):162.
[23] YAMAMOTO H, WATANABE Y, OIKAWA R, et al. BARHL2 methylation using gastric wash DNA or gastric juice exosomal DNA is a useful marker for early detection of gastric cancer in an H. pylori-Independent Manner[J]. Clin Transl Gastroenterol, 2016, 7(7):e184.
[24] WANG S, PING M, SONG B, et al. Exosomal circPRRX1 enhances doxorubicin resistance in gastric cancer by regulating miR-3064-5p/PTPN14 signaling[J]. Yonsei Med J, 2020, 61(9):750-761.
[25] WANG X, ZHANG H, BAI M, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer[J]. Mol Ther, 2018, 26(3):774-783.
[26] ZHANG Q, ZHANG H, NING T, et al. Exosome-delivered c-Met siRNA could reverse chemoresistance to cisplatin in gastric cancer[J]. Int J Nanomedicine, 2020, 15:2323-2335.
[27] WANG J, LV B, SU Y, et al. Exosome-mediated transfer of lncRNA HOTTIP promotes cisplatin resistance in gastric cancer cells by regulating HMGA1/miR-218 Axis[J]. Onco Targets Ther, 2019, 1:11325-11338.
[28] LI A, ZHAO Y, LI Y, et al. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles[J]. Drug Deliv, 2021, 28(1):1237-1255.
[29] KAWAZOE A, SHITARA K, BOKU N, et al. Current status of immunotherapy for advanced gastric cancer[J]. Jpn J Clin Oncol, 2021, 51(1):20-27.
[30] XU Z, ZENG S, GONG Z, et al. Exosome-based immunotherapy: a promising approach for cancer treatment[J]. Mol Cancer, 2020, 19(1):160.
[31] LI Z, SUO B, LONG G, et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer[J]. Front Cell Dev Biol, 2020, 8:572689.
Options
文章导航

/

〈 〉